CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 28 enrolled
Drug / intervention
Bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02665273
NCT02665273Phase 3Completed
CompareCT.gov

A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine

Montefiore Medical Center·interventional·Posted Jan 27, 2016·Updated Aug 11, 2020

In Brief

A Phase 3 clinical trial evaluating Greater occipital nerve block and Bupivacaine for Migraine. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 27, 2016
Enrollment StartJul 1, 2015
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.4 years ago

Interventions

Greater occipital nerve blockprocedure

Bilateral greater occipital nerve block

Bupivacainedrug

0.5 cc of 0.5% bupivacaine injected intradermally